1
|
Rivière P, Kanters C, Pellet G, Ni A, Hupé M, Aboulhamid N, Poullenot F, Bitton A, Zerbib F, Lakatos PL, Afif W, Laharie D, Bessissow T. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers. Inflamm Bowel Dis 2022:6653347. [PMID: 35917111 DOI: 10.1093/ibd/izac167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Indexed: 12/09/2022]
Abstract
BACKGROUND Real-life data on the efficacy of ustekinumab as first-line therapy for the treatment of luminal Crohn's disease (CD) compared with anti-tumor necrosis factor (anti-TNF) agents are lacking. We compared the clinical response rates at 3 months in 2 cohorts of biologic-naïve patients treated by ustekinumab and anti-TNF agents. METHODS Biologic-naïve patients starting either ustekinumab or an anti-TNF agent for luminal CD between 2016 and 2019 in 2 tertiary centers were retrospectively included. The primary endpoint was clinical response at 3 months, defined as a Harvey-Bradshaw Index <4 or a 3-point drop in the score without steroids, need for CD-related surgery, or treatment discontinuation owing to failure or intolerance. Patients treated with ustekinumab were matched to patients receiving anti-TNF agents by a propensity score algorithm. RESULTS We included 156 patients starting anti-TNF agents (95 adalimumab and 61 infliximab) and 50 ustekinumab. After matching, clinical response rates at 3 months were 64% and 86% in the ustekinumab and anti-TNF groups, respectively (P = .01). At 12 months, in multivariate analysis adjusted for disease duration, location, concomitant immunosuppressant and steroids, and symptoms, clinical remission was independently associated with the biological therapy received (odds ratio, 2.6 for anti-TNF agent vs ustekinumab; P = .02). With a median follow-up duration of 40 (interquartile range, 23-52) months, no difference was observed in terms of time to drug withdrawal (P = .29) or safety. CONCLUSIONS This retrospective real-world data suggest that an anti-TNF agent as a first-line biological therapy is associated with higher rates of response at 3 months than ustekinumab in patients with CD.
Collapse
Affiliation(s)
- Pauline Rivière
- INSERM CIC 1401, Gastroenterology Department, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France
| | - Caitlyn Kanters
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada
| | - Gauthier Pellet
- INSERM CIC 1401, Gastroenterology Department, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France
| | - Alexander Ni
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada
| | - Marianne Hupé
- INSERM CIC 1401, Gastroenterology Department, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France
| | - Nesrine Aboulhamid
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada
| | - Florian Poullenot
- INSERM CIC 1401, Gastroenterology Department, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France
| | - Alain Bitton
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada
| | - Frank Zerbib
- INSERM CIC 1401, Gastroenterology Department, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France
| | - Peter L Lakatos
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada
| | - Waqqas Afif
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada
| | - David Laharie
- INSERM CIC 1401, Gastroenterology Department, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France
| | - Talat Bessissow
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada
| |
Collapse
|
2
|
NIE W, Li M, Liu B, Wang J, Jin L, Zhang Y, Ni A, Xiao L, Shen X, Chen J, Lin W, Han F. POS-385 CIRCPTPN14 BINDS TO FUBP1 TO PROMOTE TRANSCRIPTION OF C-MYC IN KIDNEY FIBROSIS. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
3
|
Dang Y, van Heusden C, Gentzsch M, Steward I, Hickey A, Ni A, Rudolph J, Kreda S. 598: Correction of CF splicing mutations with oligonucleotides. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02021-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Hao G, Ni A, Chang YJ, Hall K, Lee SH, Chiu HT, Yang SF, Sheu KL, Chen SC. Improve the clinical effective decision of the oral feeding readiness in preterm infants: Revise and validate the TC-POFRAS. J Neonatal Perinatal Med 2021; 15:317-325. [PMID: 34719446 DOI: 10.3233/npm-210869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Currently there is limited information to guide health professionals regarding the optimal time frame to initiate safe and effective oral feedings to preterm infants. The study aims to revise and validate a streamlined version of the Traditional Chinese-Preterm Oral Feeding Readiness Assessment Scale, the TC-POFRAS®, and evaluate its construct validity in the clinical decisions regarding feeding readiness of preterm infants. METHODS Eighty-one clinically stable preterm infants were assessed using the TC-POFRAS for oral feeding readiness. Item-total correlation analysis was used to check if any item was inconsistent with the averaged TC-POFRAS scores. Cronbach's α coefficient was used to evaluate the inter-item consistency. Exploratory factor analysis was used to determine the coherence of variables to reorganize assessment domains. The revised version of TC-POFRAS (TC-POFRAS®) was developed and a new cut-off score based on discriminant accuracy was established. RESULTS Based on the results from statistical analysis, five items ("lips posture," "tongue posture," "biting reflex," "gag reflex," and "tongue cupping") were deleted from the original TC-POFRAS to form the TC-POFRAS®. The TC-POFRAS®'s global accuracy was 92.1%. The cut-off value of 19 was the one that presented the most optimization of sensitivity based on specificity. The TC-POFRAS® was reconstructed into corrected gestational age and five behavioral domains. CONCLUSIONS The TC-POFRAS® is considered a valid, safe, and accurate objective instrument to assist health professionals to initiate oral feeding of preterm infants.
Collapse
Affiliation(s)
- G Hao
- Department of Communication Sciences and Disorders, College of Health and Sciences, North Carolina Central University, NC, USA
| | - A Ni
- Department of Communication Sciences and Disorders, College of Health and Sciences, North Carolina Central University, NC, USA
| | - Y J Chang
- Department of Speech Language Pathology and Audiology, Chung Shan Medical University, Taichung, Taiwan, ROC.,Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC
| | - K Hall
- Department of Communication Sciences and Disorders, College of Health and Sciences, North Carolina Central University, NC, USA
| | - S H Lee
- School of Nursing, Chung Shan Medical University, Taichung, Taiwan, ROC
| | - H T Chiu
- Neonatal Intensive Care Unit, Chung Shan Medical University, Taichung, Taiwan, ROC
| | - S F Yang
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC
| | - K L Sheu
- Department of Family and Community Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC.,School of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC
| | - S C Chen
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC.,Department of Family and Community Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC.,School of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC
| |
Collapse
|
5
|
Ni A. Approach to: Chronic obstructive pulmonary disease (COPD). Mcgill J Med 2020. [DOI: 10.26443/mjm.v18i1.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the world, affecting developing and developed countries alike. Recent advancements in medical and interventional therapies have led to decreasing overall mortality rates in the last decade. Despite these improvements, COPD continues to cause significant morbidity and lost productivity. This review summarizes the pathophysiology of COPD and the work-up of a patient with suspected COPD, emphasizing pulmonary function testing, an approach to treatment, and the management of COPD exacerbations.
Collapse
|
6
|
Ni A, Al-Qahtani M, Salama E, Marinescu D, Khalil MA, Faria J, Morin N, Ghitulescu G, Vasilevsky CA, Boutros M. Trends in Colectomies for Colorectal Neoplasms in Ulcerative Colitis: a National Inpatient Sample Database Analysis over Two Decades. J Gastrointest Surg 2020; 24:1721-1728. [PMID: 32557016 DOI: 10.1007/s11605-020-04666-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2019] [Accepted: 05/25/2020] [Indexed: 01/31/2023]
Abstract
BACKGROUND Rates of colectomy for ulcerative colitis have been decreasing, particularly since the advent of biologics, but the subsequent impact of reduced colectomy rates on the development of neoplasms in chronically treated ulcerative colitis colons is unknown. PURPOSE To determine trends in colectomy for colorectal neoplasms in adult patients with ulcerative colitis. METHODS Adult admissions with ulcerative colitis were identified from the National Inpatient Sample from 1993 to 2015. The rate of colectomy with concurrent colorectal neoplasm served as the primary outcome and was evaluated using time trend linear and multivariable regression. RESULTS There were 366,286 admissions with ulcerative colitis including 16,556 (4.5%) total colectomies. Of those undergoing colectomy, 2018 (12.2%) had a concurrent diagnosis of colorectal neoplasm. The proportion of colectomies for ulcerative colitis with concurrent colorectal neoplasm increased from 10.3 to 12.5% (pTrend = 0.004). Specifically, the proportion of colectomies performed for dysplasia/benign neoplasm and rectal cancer increased from 3.5 to 5.6% (pTrend < 0.001) and from 2.6 to 3.0% (pTrend = 0.028) respectively, and those for colon cancer remained stable (4.5 to 3.9%, pTrend = 0.423). On multivariate regression, year of colectomy was a significant predictor of colectomy for colorectal neoplasm (OR = 1.044, 95% CI = 1.025-1.062). DISCUSSION Operative management of ulcerative colitis appears to be slowly increasing in oncological indications. The rising proportions of colectomies performed for colorectal neoplasms suggest the need for continued screening in these patients, including rectal surveillance.
Collapse
Affiliation(s)
- Alexander Ni
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada.,Division of Colon and Rectal Surgery, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Suite G317, Montreal, H3T 1E2, Quebec, Canada
| | - Mohammed Al-Qahtani
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada.,Division of Colon and Rectal Surgery, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Suite G317, Montreal, H3T 1E2, Quebec, Canada
| | - Ebram Salama
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada.,Division of Colon and Rectal Surgery, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Suite G317, Montreal, H3T 1E2, Quebec, Canada
| | - Daniel Marinescu
- Division of Colon and Rectal Surgery, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Suite G317, Montreal, H3T 1E2, Quebec, Canada
| | - Maria Abou Khalil
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada.,Division of Colon and Rectal Surgery, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Suite G317, Montreal, H3T 1E2, Quebec, Canada
| | - Julio Faria
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada.,Division of Colon and Rectal Surgery, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Suite G317, Montreal, H3T 1E2, Quebec, Canada
| | - Nancy Morin
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada.,Division of Colon and Rectal Surgery, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Suite G317, Montreal, H3T 1E2, Quebec, Canada
| | - Gabriela Ghitulescu
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada.,Division of Colon and Rectal Surgery, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Suite G317, Montreal, H3T 1E2, Quebec, Canada
| | - Carol-Ann Vasilevsky
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada.,Division of Colon and Rectal Surgery, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Suite G317, Montreal, H3T 1E2, Quebec, Canada
| | - Marylise Boutros
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada. .,Division of Colon and Rectal Surgery, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Suite G317, Montreal, H3T 1E2, Quebec, Canada.
| |
Collapse
|
7
|
Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol 2019; 29:2085-2091. [PMID: 30165371 DOI: 10.1093/annonc/mdy334] [Citation(s) in RCA: 204] [Impact Index Per Article: 40.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung cancers in prospective trials. In contrast, the activity of immunotherapy, PD-L1 expression and tumor mutational burden (TMB) of these tumors and are not well characterized. Patients and methods Patients with MET exon 14-altered lung cancers of any stage treated at two academic institutions were identified. A review of clinicopathologic and molecular features, and an analysis of response to single-agent or combination immune checkpoint inhibition were conducted. PD-L1 immunohistochemistry was carried out and TMB was calculated by estimation from targeted next-generation sequencing panels. Results We identified 147 patients with MET exon 14-altered lung cancers. PD-L1 expression of 0%, 1%-49%, and ≥50% were 37%, 22%, and 41%, respectively, in 111 evaluable tumor samples. The median TMB of MET exon 14-altered lung cancers was lower than that of unselected non-small-cell lung cancers (NSCLCs) in both independently evaluated cohorts: 3.8 versus 5.7 mutations/megabase (P < 0.001, n = 78 versus 1769, cohort A), and 7.3 versus 11.8 mutations/megabase (P < 0.001, n = 62 versus 1100, cohort B). There was no association between PD-L1 expression and TMB (Spearman's rho=0.18, P = 0.069). In response-evaluable patients (n = 24), the objective response rate was 17% (95% CI 6% to 36%) and the median progression-free survival was 1.9 months (95% CI 1.7-2.7). Responses were not enriched in tumors with PD-L1 expression ≥50% nor high TMB. Conclusion A substantial proportion of MET exon 14-altered lung cancers express PD-L1, but the median TMB is lower compared with unselected NSCLCs. Occasional responses to PD-1 blockade can be achieved, but overall clinical efficacy is modest.
Collapse
Affiliation(s)
- J K Sabari
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - G C Leonardi
- Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - C A Shu
- Division of Hematology Oncology, Department of Medicine, Columbia University, New York, USA
| | - R Umeton
- Department of Informatics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - J Montecalvo
- Department of Pathology, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA
| | - A Ni
- Department of Epidemiology and Biostatistics, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA
| | - R Chen
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - J Dienstag
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - C Mrad
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - I Bergagnini
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - W V Lai
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - M Offin
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - K C Arbour
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - A J Plodkowski
- Department of Radiology, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA
| | - D F Halpenny
- Department of Radiology, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA
| | - P K Paik
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - B T Li
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA; Department of Early Drug Development Service, Division of Solid Tumor Oncology, Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA
| | - G J Riely
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - M G Kris
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - C M Rudin
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - L M Sholl
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
| | - M Nishino
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA; Department of Radiology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - M D Hellmann
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA
| | - N Rekhtman
- Department of Informatics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - M M Awad
- Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - A Drilon
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA; Department of Early Drug Development Service, Division of Solid Tumor Oncology, Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA.
| |
Collapse
|
8
|
Jatana C, Jacobs T, Towning C, Guo X, Ni A, Towning L. The Addition of Platelet-Rich-Fibrin in Socket Preservation for Future Dental Implant Placement: A Randomized Controlled Clinical Trial. J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.joms.2019.06.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Ghione P, Cordeiro P, Ni A, Hu Q, Ganesan N, Galasso N, Dogan A, Horwitz S. RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA-ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS. Hematol Oncol 2019. [DOI: 10.1002/hon.62_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Ghione
- Lymphoma service; Memorial Sloan Ketterin Cancer Center; New York United States
| | - P.G. Cordeiro
- Department of Surgery; Memorial Sloan Kettering Cancer Center, Plastic and Reconstructive Surgery Service; New York United States
| | - A. Ni
- Biostatistics Department; Memorial Sloan Kettering Cancer Center; New York United States
| | - Q. Hu
- Department of Surgery; Memorial Sloan Kettering Cancer Center, Plastic and Reconstructive Surgery Service; New York United States
| | - N. Ganesan
- Lymphoma service; Memorial Sloan Ketterin Cancer Center; New York United States
| | - N. Galasso
- Lymphoma service; Memorial Sloan Ketterin Cancer Center; New York United States
| | - A. Dogan
- Hematopathology Service; Memorial Sloan Kettering Cancer Center; New York United States
| | - S.M. Horwitz
- Lymphoma service; Memorial Sloan Ketterin Cancer Center; New York United States
| |
Collapse
|
10
|
Matasar M, Qiu A, Shapouri S, Drill E, Schade J, Ravelo A, Ni A, To T, Dawson K. REAL-WORLD ASSESSMENT OF PRACTICE EFFICIENCY WITH THE INTRODUCTION OF SUBCUTANEOUS RITUXIMAB. Hematol Oncol 2019. [DOI: 10.1002/hon.226_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M.J. Matasar
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A. Qiu
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - S. Shapouri
- US Medical Affairs; Genentech, Inc.; South San Francisco CA United States
| | - E.N. Drill
- Department of Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - J. Schade
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A. Ravelo
- US Medical Affairs; Genentech, Inc.; South San Francisco CA United States
| | - A. Ni
- Department of Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - T.M. To
- US Medical Affairs; Genentech, Inc.; South San Francisco CA United States
| | - K.L. Dawson
- US Medical Affairs; Genentech, Inc.; South San Francisco CA United States
| |
Collapse
|
11
|
Batlevi C, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz C, Noy A, Palomba M, Portlock C, Straus D, Boccomini C, Tucci A, Zelenetz A, Seshan V, Luminari S, Marcheselli L, Federico M, Younes A. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.109_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C.L. Batlevi
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - F. Sha
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Alperovich
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Ni
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - K. Smith
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - Z. Ying
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - P. Hamlin
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S.M. Horwitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Kumar
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M. Matasar
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A.J. Moskowitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C.H. Moskowitz
- Department of Medicine; University of Miami, Sylvester Cancer Center; Miami United States
| | - A. Noy
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M.L. Palomba
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Portlock
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - D. Straus
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Boccomini
- ASO Città della Salute e della Scienza di Torino; Ematologia; Turin Italy
| | - A. Tucci
- Department of Hematology; Spedali Civili di Brescia; Brescia Italy
| | - A.D. Zelenetz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - V.E. Seshan
- Department of Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York United States
| | - S. Luminari
- Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine, Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine; University of Modena and Reggio Emilia; Modena Italy
| | - L. Marcheselli
- Department of Medical and Surgical Sciences, and FIL Trial Office; University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine, Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine; University of Modena and Reggio Emilia; Modena Italy
| | - A. Younes
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| |
Collapse
|
12
|
Sun Y, Liu Y, Li Y, Bai H, Ni A, Chen J. 307 Identification and differential expression of microRNAs in the testis of chicken with high and low sperm motility. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Y Sun
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| | - Y Liu
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| | - Y Li
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| | - H Bai
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| | - A Ni
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| | - J Chen
- Institute of Animal Science, Chinese Academy of Agricultural Sciences,Beijing, China
| |
Collapse
|
13
|
Zauderer M, Muller S, Lai W, Ni A, Jungbluth A, Ginsberg M, Daly R, Hellmann M, Ladanyi M, Sauter J. P2.06-40 VISTA is Highly Expressed in Malignant Pleural Mesothelioma (MPM) and Independent of PD-L1 Expression. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
14
|
Arbour K, Shen R, Plodkowski A, Rizvi H, Ni A, Long N, Halpenny D, Sanchez-Vega F, Rudin C, Riely G, Hellmann M. MA19.09 Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.480] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
15
|
Ponce S, Allison MA, Swett K, Cai J, Desai AA, Hurwitz BE, Ni A, Schneiderman N, Shah SJ, Spevack DM, Talavera GA, Rodriguez CJ. The associations between anthropometric measurements and left ventricular structure and function: the Echo-SOL Study. Obes Sci Pract 2018; 4:387-395. [PMID: 30151233 PMCID: PMC6105700 DOI: 10.1002/osp4.279] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 04/13/2018] [Accepted: 04/26/2018] [Indexed: 12/30/2022] Open
Abstract
OBJECTIVE The objective of this study is to determine associations between anthropometry and echocardiographic measures of cardiac structure and function in Hispanic/Latinos. METHODS A total of 1,824 participants from ECHO-SOL were included. We evaluated associations between echocardiographic measures of left ventricular structure and function and anthropometric measures using multivariable-adjusted linear and logistic regression models adjusting for traditional cardiovascular risk factors. RESULTS The mean age was 56 ± 0.17 years, 57% were women. The mean body mass index (BMI) was 30 ± 9.4 kg m-2, waist circumference (WC) was 100 ± 18 cm, and waist-to-hip ratio (WHR) was 0.93 ± 0.15. Adjusted analysis showed that 5-unit increment in BMI and 5-cm increase in WC was associated with 3.4 ± 0.6 and 1.05 ± 0.05 g m-2.7 (p < 0.05 for both) higher left ventricular (LV) mass index, respectively. Similarly, 0.1-unit increment in WHR was associated with 2.0 ± 0.16 g m-2.7 higher LV mass index (p < 0.01). WHR was associated with 0.22 ± 0.08% decrease in ejection fraction (p < 0.05). Concomitantly, 5-unit increment in BMI and WC was associated with increased odds of abnormal LV geometry (odds ratio 1.40 and 1.16, p = 0.03 and <0.01, respectively); 0.1-unit increment in WHR was associated with increased odds of abnormal LV geometry (odds ratio 1.51, p < 0.01). CONCLUSIONS Among Hispanic/Latinos, higher anthropometric measures were associated with adverse cardiac structure and function.
Collapse
Affiliation(s)
- S. Ponce
- Family Medicine and Public Health DepartmentUniversity of California San DiegoLa JollaCAUSA
| | - M. A. Allison
- Family Medicine and Public Health DepartmentUniversity of California San DiegoLa JollaCAUSA
| | - K. Swett
- Biostatistics DepartmentUniversity of North CarolinaChapel HillNCUSA
| | - J. Cai
- Biostatistics DepartmentUniversity of North CarolinaChapel HillNCUSA
| | - A. A. Desai
- Department of MedicineUniversity of ArizonaTucsonAZUSA
| | - B. E. Hurwitz
- Department of PsychologyUniversity of MiamiCoral GablesFLUSA
| | - A. Ni
- Biostatistics DepartmentUniversity of North CarolinaChapel HillNCUSA
| | - N. Schneiderman
- Department of PsychologyUniversity of MiamiCoral GablesFLUSA
| | - S. J. Shah
- Department of MedicineNorthwestern UniversityEvanstonILUSA
| | - D. M. Spevack
- Department of MedicineAlbert Einstein College of MedicineBronxNYUSA
| | - G. A. Talavera
- Graduate School of Public HealthSan Diego State UniversitySan DiegoCAUSA
| | - C. J. Rodriguez
- Epidemiology and PreventionWake Forest UniversityWinston‐SalemNCUSA
| |
Collapse
|
16
|
Bai H, Sun Y, Liu N, Liu Y, Xue F, Li Y, Xu S, Ni A, Ye J, Chen Y, Chen J. Genome-wide detection of CNVs associated with beak deformity in chickens using high-density 600K SNP arrays. Anim Genet 2018; 49:226-236. [PMID: 29642269 DOI: 10.1111/age.12652] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/07/2018] [Indexed: 11/30/2022]
Abstract
Beak deformity (crossed beaks) is found in several indigenous chicken breeds including Beijing-You studied here. Birds with deformed beaks have reduced feed intake and poor production performance. Recently, copy number variation (CNV) has been examined in many species and is recognized as a source of genetic variation, especially for disease phenotypes. In this study, to unravel the genetic mechanisms underlying beak deformity, we performed genome-wide CNV detection using Affymetrix chicken high-density 600K data on 48 deformed-beak and 48 normal birds using penncnv. As a result, two and eight CNV regions (CNVRs) covering 0.32 and 2.45 Mb respectively on autosomes were identified in deformed-beak and normal birds respectively. Further RT-qPCR studies validated nine of the 10 CNVRs. The ratios of six CNVRs were significantly different between deformed-beak and normal birds (P < 0.01). Within these six regions, three and 21 known genes were identified in deformed-beak and normal birds respectively. Bioinformatics analysis showed that these genes were enriched in six GO terms and one KEGG pathway. Five candidate genes in the CNVRs were further validated using RT-qPCR. The expression of LRIG2 (leucine rich repeats and immunoglobulin like domains 2) was lower in birds with deformed beaks (P < 0.01). Therefore, the LRIG2 gene could be considered a key factor in view of its known functions and its potential roles in beak deformity. Overall, our results will be helpful for future investigations of the genomic structural variations underlying beak deformity in chickens.
Collapse
Affiliation(s)
- H Bai
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - Y Sun
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - N Liu
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - Y Liu
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - F Xue
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - Y Li
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - S Xu
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - A Ni
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - J Ye
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| | - Y Chen
- Beijing General Station of Animal Husbandry Service, Beijing, 102200, China
| | - J Chen
- Key Laboratory of Animal Genetics Breeding and Reproduction (Poultry), Ministry of Agriculture, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, 100193, China
| |
Collapse
|
17
|
Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 2017; 28:583-589. [PMID: 27998967 DOI: 10.1093/annonc/mdw640] [Citation(s) in RCA: 441] [Impact Index Per Article: 63.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Background Programmed cell death protein-1 (PD-1) blockade therapies have demonstrated durable responses and prolonged survival in a variety of malignancies. Treatment is generally well tolerated although immune-related adverse events (irAEs) can occur. Autoimmune thyroid dysfunction is among the most common irAE, but an assessment of the clinical, mechanistic, and immunologic features has not been previously described. Patient and methods Patients with advanced non-small-cell lung cancer (NSCLC) treated with pembrolizumab at Memorial Sloan Kettering Cancer Center (n = 51) as part of KEYNOTE-001 (NCT01295827) were included. Thyroid function test and anti-thyroid antibodies were assessed prospectively at each study visit, beginning before the first treatment. Frequency of development of thyroid dysfunction, association with anti-thyroid antibodies, clinical course, and relationship with progression-free survival and overall survival to treatment with pembrolizumab was evaluated. Results Of 51 patients treated, 3 were hypothyroid and 48 were not at baseline. Ten of 48 [21%, 95% confidence interval (CI) 10% to 35%] patients developed thyroid dysfunction requiring thyroid replacement. Anti-thyroid antibodies were present in 8 of 10 patients who developed thyroid dysfunction, compared with 3 of 38 who did not (80% versus 8%, P < 0.0001). Thyroid dysfunction occurred early (median, 42 days) in the pembrolizumab course, and a majority (6 of 10 patients) experienced brief, transient hyperthyroidism preceding the onset of hypothyroidism; no persistent hyperthyroidism occurred. Both hyperthyroidism and hypothyroidism were largely asymptomatic. Overall survival with pembrolizumab was significantly longer in subjects who developed thyroid dysfunction (hazard ratio, 0.29; 95% CI 0.09-0.94; P = 0.04). Conclusions Thyroid dysfunction during pembrolizumab treatment of NSCLC is common and is characterized by early-onset, frequently preceded by transient hyperthyroidism, closely associated with anti-thyroid antibodies, and may be associated with improved outcomes. The presence of antibody-mediated toxicity in T-cell-directed therapy suggests an under-recognized impact of PD-1 biology in modulating humoral immunity.
Collapse
Affiliation(s)
- J C Osorio
- Department of Medicine, Weill Cornell Medical College, New York, USA
| | - A Ni
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J E Chaft
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - R Pollina
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - M K Kasler
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - D Stephens
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - C Rodriguez
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - L Cambridge
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - H Rizvi
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J D Wolchok
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA,Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering, New York, , USA,Ludwig Institute for Cancer Research, New York, USA
| | - T Merghoub
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA,Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering, New York, , USA,Ludwig Institute for Cancer Research, New York, USA
| | - C M Rudin
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - S Fish
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - M D Hellmann
- Department of Medicine, Weill Cornell Medical College, New York, USA,Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA,Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering, New York, , USA
| |
Collapse
|
18
|
Li B, Shen R, Buonocore D, Olah Z, Ni A, Ginsberg M, Ulaner G, Weber W, Tsui D, Offin M, Won H, Ladanyi M, Riely G, Solit D, Hyman D, Rudin C, Berger M, Baselga J, Scaltriti M, Arcila M, Kris M. OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.410] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Sauter C, Riviere I, Senechal B, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Moskowitz C, Giralt S, Matasar M, Curran K, Park J, Sadelain M, Brentjens R. A PHASE I TRIAL OF 19-28Z CAR-T CELLS POST-HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT-ASCT) FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_128] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Sauter
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - I. Riviere
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - B. Senechal
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - Y. Bernal
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - X. Wang
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - T. Purdon
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Hall
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Moskowitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Giralt
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Matasar
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - K. Curran
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Park
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Sadelain
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Brentjens
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
20
|
Batlevi C, Alperovich A, Ni A, Soumerai J, Smith K, Ying Z, Caron P, Drullinsky P, Gerecitano J, Hamilton A, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz C, Noy A, Palomba M, Portlock C, Sauter C, Straus D, Zelenetz A, Seshan V, Younes A. DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_92] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | - A. Ni
- Biostatistics, MKSCC; New York USA
| | | | | | - Z. Ying
- Hematology; Peking University Cancer Hospital; Beijing China
| | | | | | | | | | | | | | | | | | | | | | - A. Noy
- Lymphoma, MSKCC; New York USA
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Batlevi C, Hamlin P, Matasar M, Gerecitano J, Drullinsky P, Hamilton A, Straus D, Horwitz S, Kumar A, Moskowitz C, Moskowitz A, Zelenetz A, Ahsanuddin S, Callan D, Freidin B, Porzio R, Soiffer J, Copeland A, Dang T, Rademaker J, Schoder H, Ni A, Younes A. PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_38] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Batlevi
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Hamlin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Matasar
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Gerecitano
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Drullinsky
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Hamilton
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - D. Straus
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Horwitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Kumar
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Moskowitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Moskowitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Zelenetz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Ahsanuddin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - D. Callan
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - B. Freidin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Porzio
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Soiffer
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Copeland
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - T. Dang
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Rademaker
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - H. Schoder
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Younes
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
22
|
Moskowitz A, Schöder H, Gavane S, Thoren K, Fleisher M, Yahalom J, McCall S, Fox S, Gerecitano J, Grewal R, Hamlin P, Horwitz S, Kumar A, Matasar M, Ni A, Noy A, Palomba M, Perales M, Portlock C, Sauter C, Straus D, Younes A, Zelenetz A, Moskowitz C. BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET-ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_17] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A.J. Moskowitz
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - H. Schöder
- Nuclear Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Gavane
- Nuclear Medicine; Mt. Sinai Hospital; New York USA
| | - K.L. Thoren
- Clinical Chemistry Service; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Fleisher
- Clinical Chemistry Service; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Yahalom
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - S.J. McCall
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - S.Y. Fox
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Gerecitano
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Grewal
- Nuclear Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P.A. Hamlin
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Horwitz
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Kumar
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Matasar
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Biostatistics; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Noy
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - M.L. Palomba
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Perales
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - C.S. Portlock
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Sauter
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - D. Straus
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Younes
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - A.D. Zelenetz
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| | - C.H. Moskowitz
- Lymphoma; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
23
|
Soumerai J, Ni A, Batlevi C, Alperovich A, Bantilan K, Palomba M, Gerecitano J, Noy A, Hamlin P, Moskowitz C, Copeland A, Matasar M, Drullinsky P, Hamilton A, Horwitz S, Intlekofer A, Kumar A, Moskowitz A, Portlock C, Sauter C, Straus D, Caron P, Ying Z, Smith K, Younes A, Zelenetz A. TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J.D. Soumerai
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Batlevi
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Alperovich
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - K.S. Bantilan
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Palomba
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - J.F. Gerecitano
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Noy
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Hamlin
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C.H. Moskowitz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A.R. Copeland
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - M.J. Matasar
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - P.R. Drullinsky
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Hamilton
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - S.M. Horwitz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A.M. Intlekofer
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Kumar
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Moskowitz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Portlock
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Sauter
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - D.J. Straus
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Caron
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - Z. Ying
- Medicine, Royal Marsden Hospital; Beigene China
| | - K. Smith
- Medicine, Royal Marsden Hospital; London UK
| | - A. Younes
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A.D. Zelenetz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
24
|
Ho AL, Dunn L, Sherman EJ, Fury MG, Baxi SS, Chandramohan R, Dogan S, Morris LGT, Cullen GD, Haque S, Sima CS, Ni A, Antonescu CR, Katabi N, Pfister DG. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol 2016; 27:1902-8. [PMID: 27566443 DOI: 10.1093/annonc/mdw287] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Accepted: 07/19/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Recurrent/metastatic adenoid cystic carcinoma (ACC) is an incurable disease with no standard treatments. The majority of ACCs express the oncogenic transcription factor MYB (also c-myb), often in the context of a MYB gene rearrangement. This phase II trial of the tyrosine kinase inhibitor (TKI) axitinib (Pfizer) tested the hypothesis that targeting pathways activated by MYB can be therapeutically effective for ACC. PATIENTS AND METHODS This is a minimax two-stage, phase II trial that enrolled patients with incurable ACC of any primary site. Progressive or symptomatic disease was required. Patients were treated with axitinib 5 mg oral twice daily; dose escalation was allowed. The primary end point was best overall response (BOR). An exploratory analysis correlating biomarkers to drug benefit was conducted, including next-generation sequencing (NGS) in 11 patients. RESULTS Thirty-three patients were registered and evaluable for response. Fifteen patients had the axitinib dose increased. Tumor shrinkage was achieved in 22 (66.7%); 3 (9.1%) had confirmed partial responses. Twenty-five (75.8%) patients had stable disease, 10 of whom had disease stability for >6 months. The median progression-free survival (PFS) was 5.7 months (range 0.92-21.8 months). Grade 3 axitinib-related toxicities included hypertension, oral pain and fatigue. A trend toward superior PFS was noted with the MYB/NFIB rearrangement, although this was not statistically significant. NGS revealed three tumors with 4q12 amplification, producing increased copies of axitinib-targeted genes PDGFR/KDR/KIT. Two 4q12 amplified patients achieved stable disease for >6 months, including one with significant tumor reduction and the longest PFS on study (21.8 months). CONCLUSIONS Although the primary end point was not met, axitinib exhibited clinical activity with tumor shrinkage achieved in the majority of patients with progressive disease before trial enrollment. Analysis of MYB biomarkers and genomic profiling suggests the hypothesis that 4q12 amplified ACCs are a disease subset that benefit from TKI therapy.
Collapse
Affiliation(s)
- A L Ho
- Department of Medicine Department of Medicine
| | | | - E J Sherman
- Department of Medicine Department of Medicine
| | - M G Fury
- Department of Medicine Department of Medicine
| | - S S Baxi
- Department of Medicine Department of Medicine
| | | | | | - L G T Morris
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, USA
| | | | - S Haque
- Department of Radiology Department of Radiology, Weill Cornell Medical College, New York City
| | - C S Sima
- Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, USA
| | - A Ni
- Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, USA
| | | | | | - D G Pfister
- Department of Medicine Department of Medicine
| |
Collapse
|
25
|
Sako H, Ahn JK, Baek KY, Bassalleck B, Fujioka H, Guo L, Hasegawa S, Hicks K, Honda R, Hwang SH, Ichikawa Y, Ieiri M, Imai K, Kim SH, Kiuchi R, Lee HS, Nakazawa K, Naruki M, Ni A, Niiyama M, Ozawa K, Park JY, Park SH, Ryu SY, Sato S, Shirotori K, Sugimura H, Sumihara M, Tanida K, Takahashi H, Takahashi T. Search for H-dibaryon at J-PARC with a Large Acceptance TPC. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146609015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Baillie N, Tkachenko S, Zhang J, Bosted P, Bültmann S, Christy ME, Fenker H, Griffioen KA, Keppel CE, Kuhn SE, Melnitchouk W, Tvaskis V, Adhikari KP, Adikaram D, Aghasyan M, Amaryan MJ, Anghinolfi M, Arrington J, Avakian H, Baghdasaryan H, Battaglieri M, Biselli AS, Branford D, Briscoe WJ, Brooks WK, Burkert VD, Carman DS, Celentano A, Chandavar S, Charles G, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Daniel A, Dashyan N, De Vita R, De Sanctis E, Deur A, Dey B, Djalali C, Dodge G, Domingo J, Doughty D, Dupre R, Dutta D, Ent R, Egiyan H, El Alaoui A, El Fassi L, Elouadrhiri L, Eugenio P, Fedotov G, Fegan S, Fradi A, Gabrielyan MY, Gevorgyan N, Gilfoyle GP, Giovanetti KL, Girod FX, Gohn W, Golovatch E, Gothe RW, Graham L, Guegan B, Guidal M, Guler N, Guo L, Hafidi K, Heddle D, Hicks K, Holtrop M, Hungerford E, Hyde CE, Ilieva Y, Ireland DG, Ispiryan M, Isupov EL, Jawalkar SS, Jo HS, Kalantarians N, Khandaker M, Khetarpal P, Kim A, Kim W, King PM, Klein A, Klein FJ, Klimenko A, Kubarovsky V, Kuleshov SV, Kvaltine ND, Livingston K, Lu HY, MacGregor IJD, Mao Y, Markov N, McKinnon B, Mineeva T, Morrison B, Moutarde H, Munevar E, Nadel-Turonski P, Ni A, Niccolai S, Niculescu I, Niculescu G, Osipenko M, Ostrovidov AI, Pappalardo L, Park K, Park S, Pasyuk E, Anefalos Pereira S, Pisano S, Pozdniakov S, Price JW, Procureur S, Prok Y, Protopopescu D, Raue BA, Ricco G, Rimal D, Ripani M, Rosner G, Rossi P, Sabatié F, Saini MS, Salgado C, Schott D, Schumacher RA, Seder E, Sharabian YG, Sober DI, Sokhan D, Stepanyan S, Stepanyan SS, Stoler P, Strauch S, Taiuti M, Tang W, Ungaro M, Vineyard MF, Voutier E, Watts DP, Weinstein LB, Weygand DP, Wood MH, Zana L, Zhao B. Measurement of the neutron F2 structure function via spectator tagging with CLAS. Phys Rev Lett 2012; 108:142001. [PMID: 22540786 DOI: 10.1103/physrevlett.108.142001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2011] [Indexed: 05/31/2023]
Abstract
We report on the first measurement of the F(2) structure function of the neutron from the semi-inclusive scattering of electrons from deuterium, with low-momentum protons detected in the backward hemisphere. Restricting the momentum of the spectator protons to ≲100 MeV/c and their angles to ≳100° relative to the momentum transfer allows an interpretation of the process in terms of scattering from nearly on-shell neutrons. The F(2)(n) data collected cover the nucleon-resonance and deep-inelastic regions over a wide range of Bjorken x for 0.65<Q(2)<4.52 GeV(2), with uncertainties from nuclear corrections estimated to be less than a few percent. These measurements provide the first determination of the neutron to proton structure function ratio F(2)(n)/F(2)(p) at 0.2≲x≲0.8 with little uncertainty due to nuclear effects.
Collapse
Affiliation(s)
- N Baillie
- College of William and Mary, Williamsburg, Virginia 23187, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Feber J, Gaboury I, Ni A, Alos N, Arora S, Bell L, Blydt-Hansen T, Clarson C, Filler G, Hay J, Hebert D, Lentle B, Matzinger M, Midgley J, Moher D, Pinsk M, Rauch F, Rodd C, Shenouda N, Siminoski K, Ward LM. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. Osteoporos Int 2012; 23:751-60. [PMID: 21494860 PMCID: PMC4000256 DOI: 10.1007/s00198-011-1621-2] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Accepted: 03/02/2011] [Indexed: 01/27/2023]
Abstract
SUMMARY Eighty children with nephrotic syndrome underwent lumbar spine densitometry and vertebral morphometry soon after glucocorticoid initiation. We found an inverse relationship between glucocorticoid exposure and spine areal bone mineral density (BMD) Z-score and a low rate of vertebral deformities (8%). INTRODUCTION Vertebral fractures are an under-recognized complication of childhood glucocorticoid-treated illnesses. Our goal was to study the relationships among glucocorticoid exposure, lumbar spine areal BMD (LS BMD), and vertebral shape in glucocorticoid-treated children with new-onset nephrotic syndrome. METHODS Lateral thoracolumbar spine radiography and LS BMD were performed in 80 children with nephrotic syndrome (median age 4.4 years; 46 boys) within the first 37 days of glucocorticoid therapy. Genant semiquantitative grading was used as the primary method for vertebral morphometry; the algorithm-based qualitative (ABQ) method was used for secondary vertebral deformity analysis. RESULTS Six of the 78 children with usable radiographs (8%; 95% confidence interval 4 to 16%) manifested a single Genant grade 1 deformity each. All deformities were mild anterior wedging (two at each of T6, T7, and T8). Four of the 78 children (5%; 95% confidence interval 2 to 13%) showed one ABQ sign of fracture each (loss of endplate parallelism; two children at T6 and two at T8). Two of the children with ABQ signs also had a Genant grade 1 deformity in the same vertebral body. None of the children with a Genant or ABQ deformity reported back pain. An inverse relationship was identified between LS BMD Z-score and glucocorticoid exposure. CONCLUSIONS Although we identified an inverse relationship between steroid exposure and LS BMD soon after glucocorticoid initiation for childhood nephrotic syndrome, there was only a low rate of vertebral deformities. The clinical significance of these findings requires further study.
Collapse
Affiliation(s)
- J Feber
- University of Ottawa, Ottawa, ON, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Wood MH, Nasseripour R, Paolone M, Djalali C, Weygand DP, Adhikari KP, Anghinolfi M, Ball J, Battaglieri M, Batourine V, Bedlinskiy I, Bellis M, Berman BL, Biselli AS, Branford D, Briscoe WJ, Brooks WK, Burkert VD, Careccia SL, Carman DS, Cole PL, Collins P, Crede V, D'Angelo A, Daniel A, De Vita R, De Sanctis E, Deur A, Dey B, Dhamija S, Dickson R, Doughty D, Dupre R, Egiyan H, El Alaoui A, El Fassi L, Eugenio P, Fegan S, Gabrielyan MY, Garçon M, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gohn W, Gothe RW, Graham L, Guidal M, Guo L, Hafidi K, Hakobyan H, Hanretty C, Hassall N, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Ishkhanov BS, Jawalkar SS, Jo HS, Joo K, Keller D, Khandaker M, Khetarpal P, Kim A, Kim W, Klein A, Klein FJ, Konczykowski P, Kubarovsky V, Kuleshov SV, Kuznetsov V, Livingston K, Martinez D, Mayer M, McAndrew J, McCracken ME, McKinnon B, Meyer CA, Mineeva T, Mirazita M, Mokeev V, Moreno B, Moriya K, Morrison B, Munevar E, Nadel-Turonski P, Ni A, Niccolai S, Niculescu G, Niculescu I, Niroula MR, Osipenko M, Ostrovidov AI, Paremuzyan R, Park K, Park S, Pasyuk E, Anefalos Pereira S, Pisano S, Pogorelko O, Pozdniakov S, Price JW, Procureur S, Prok Y, Protopopescu D, Raue BA, Ricco G, Ripani M, Rosner G, Rossi P, Sabatié F, Saini MS, Salamanca J, Salgado C, Schott D, Schumacher RA, Seder E, Seraydaryan H, Sharabian YG, Smith GD, Sober DI, Sokhan D, Stepanyan S, Stepanyan SS, Stoler P, Strakovsky II, Strauch S, Taiuti M, Tang W, Taylor CE, Tedeschi DJ, Tkachenko S, Ungaro M, Vernarsky B, Vineyard MF, Voutier E, Watts DP, Weinstein LB, Zhang J, Zhao B, Zhao ZW. Absorption of the ω and ϕ mesons in nuclei. Phys Rev Lett 2010; 105:112301. [PMID: 20867566 DOI: 10.1103/physrevlett.105.112301] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2010] [Indexed: 05/29/2023]
Abstract
Because of their long lifetimes, the ω and ϕ mesons are the ideal candidates for the study of possible modifications of the in-medium meson-nucleon interaction through their absorption inside the nucleus. During the E01-112 experiment at the Thomas Jefferson National Accelerator Facility, the mesons were photoproduced from 2H, C, Ti, Fe, and Pb targets. This Letter reports the first measurement of the ratio of nuclear transparencies for the e+e- channel. The ratios indicate larger in-medium widths compared with what have been reported in other reaction channels. The absorption of the ω meson is stronger than that reported by the CBELSA-TAPS experiment and cannot be explained by recent theoretical models.
Collapse
Affiliation(s)
- M H Wood
- Canisius College, Buffalo, New York 14208, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Huber AM, Gaboury I, Cabral DA, Lang B, Ni A, Stephure D, Taback S, Dent P, Ellsworth J, LeBlanc C, Saint-Cyr C, Scuccimarri R, Hay J, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res (Hoboken) 2010; 62:516-26. [PMID: 20391507 DOI: 10.1002/acr.20171] [Citation(s) in RCA: 106] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Vertebral fractures are an under-recognized problem in children with inflammatory disorders. We studied spine health among 134 children (87 girls) with rheumatic conditions (median age 10 years) within 30 days of initiating glucocorticoid therapy. METHODS Children were categorized as follows: juvenile dermatomyositis (n = 30), juvenile idiopathic arthritis (n = 28), systemic lupus erythematosus and related conditions (n = 26), systemic arthritis (n = 22), systemic vasculitis (n = 16), and other conditions (n = 12). Thoracolumbar spine radiograph and dual x-ray absorptiometry for lumbar spine (L-spine) areal bone mineral density (BMD) were performed within 30 days of glucocorticoid initiation. Genant semiquantitative grading was used for vertebral morphometry. Second metacarpal morphometry was carried out on a hand radiograph. Clinical factors including disease and physical activity, calcium and vitamin D intake, cumulative glucocorticoid dose, underlying diagnosis, L-spine BMD Z score, and back pain were analyzed for association with vertebral fracture. RESULTS Thirteen vertebral fractures were noted in 9 children (7%). Of these, 6 patients had a single vertebral fracture and 3 had 2-3 fractures. Fractures were clustered in the mid-thoracic region (69%). Three vertebral fractures (23%) were moderate (grade 2); the others were mild (grade 1). For the entire cohort, mean +/- SD L-spine BMD Z score was significantly different from zero (-0.55 +/- 1.2, P < 0.001) despite a mean height Z score that was similar to the healthy average (0.02 +/- 1.0, P = 0.825). Back pain was highly associated with increased odds for fracture (odds ratio 10.6 [95% confidence interval 2.1-53.8], P = 0.004). CONCLUSION In pediatric rheumatic conditions, vertebral fractures can be present prior to prolonged glucocorticoid exposure.
Collapse
Affiliation(s)
- A M Huber
- Dalhousie University, Halifax, Nova Scotia, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Walton SG, Lock EH, Ni A, Baraket M, Fernsler RF, Pappas DD, Strawhecker KE, Bujanda AA. Study of plasma-polyethylene interactions using electron beam-generated plasmas produced in Ar/SF6 mixtures. J Appl Polym Sci 2010. [DOI: 10.1002/app.32249] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
31
|
Kovesi T, Zaloum C, Stocco C, Fugler D, Dales RE, Ni A, Barrowman N, Gilbert NL, Miller JD. Heat recovery ventilators prevent respiratory disorders in Inuit children. Indoor Air 2009; 19:489-499. [PMID: 19719534 DOI: 10.1111/j.1600-0668.2009.00615.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
UNLABELLED Inuit infants have high rates of reported hospitalization for respiratory infection, associated with overcrowding and reduced ventilation. We performed a randomized, double-blind, placebo controlled trial to determine whether home heat recovery ventilators (HRV) would improve ventilation and reduce the risk of respiratory illnesses in young Inuit children. Inuit children under 6 years of age living in several communities in Nunavut, Canada were randomized to receive an active or placebo HRV. We monitored respiratory symptoms, health center encounters, and indoor air quality for 6 months. HRVs were placed in 68 homes, and 51 houses could be analyzed. Subjects had a mean age of 26.8 months. Active HRVs brought indoor carbon dioxide concentrations to within recommended concentrations. Relative humidity was also reduced. Use of HRV, compared with placebo, was associated with a progressive fall in the odds ratio for reported wheeze of 12.3% per week (95%CI 1.9-21.6%, P = 0.022). Rates of reported rhinitis were significantly lower in the HRV group than the placebo group in month 1 (odds ratio 0.20, 95%CI 0.058-0.69, P = 0.011) and in month 4 (odds ratio 0.24, 95%CI 0.054-0.90, P = 0.035). There were no significant reductions in the number of health center encounters, and there were no hospitalizations. Use of HRVs was associated with in improvement in air quality and reductions in reported respiratory symptoms in Inuit children. PRACTICAL IMPLICATIONS Reduced ventilation is common in the houses of Inuit children in arctic Canada, and is associated with an increased risk of respiratory infection. Installation of HRV brings indoor carbon dioxide concentration, as a marker of adequate ventilation, to within recommended concentrations, although relative humidity is also reduced. Installation of HRV is associated with improvements in indoor air quality, and a reduced risk of wheezing and rhinitis not associated with cold air exposure in young Inuit children. Further research is required to explore traditional Inuit cultural attitudes about air movement in dwellings.
Collapse
Affiliation(s)
- T Kovesi
- Department of Paediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Goel DP, Buckley R, deVries G, Abelseth G, Ni A, Gray R. Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial. ACTA ACUST UNITED AC 2009; 91:388-94. [PMID: 19258618 DOI: 10.1302/0301-620x.91b3.20820] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The incidence of deep-vein thrombosis and the need for thromboprophylaxis following isolated trauma below the knee is uncertain. We have investigated this with a prospective randomised double-blind controlled trial using low molecular weight heparin with saline injection as placebo in patients aged between 18 and 75 years who had sustained an isolated fracture below the knee which required operative fixation. All patients had surgery within 48 hours of injury and were randomised to receive either the placebo or low molecular weight heparin for 14 days, after which they underwent bilateral lower limb venography, interpreted by three independent radiologists. Further follow-up was undertaken at two, six, eight and 12 weeks. A total of 238 patients fulfilled all the inclusion criteria, with 127 in the low molecular weight heparin group and 111 in the placebo group, all of whom underwent bilateral venography. There was no statistically significant difference in the incidence of deep-vein thrombosis between those patients treated with low molecular weight heparin or the placebo (p = 0.22). The number of deep-vein thromboses in the two groups was 11 (8.7%) and 14 (12.6%), respectively. Age and the type of fracture were significantly associated with the rate of deep-vein thrombosis (p = 0.001 and p = 0.009, respectively) but gender, comorbidities and the body mass index were not. The overall incidence of deep-vein thrombosis in this series was 11%. There was no clinical or statistical significant reduction in the incidence of deep-vein thrombosis with the use of thromboprophylaxis. However, we accept that owing to a cessation of funding, recruitment to this trial had to be ended prior to establishing the necessary sample size. Our results cannot, therefore, categorically exclude the possibility that low molecular weight heparin treatment could be beneficial. We recommend a further multicentre trial be undertaken to resolve this matter.
Collapse
Affiliation(s)
- D P Goel
- Department of Orthopaedics, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
| | | | | | | | | | | |
Collapse
|
33
|
Abstract
The gene encoding rat bradykinin B1 receptor has been cloned by using a partial rat B1 cDNA probe. The rat B1 receptor gene contains two exons and the entire coding region is within the second exon. The 5'-flanking region of the rat B1 receptor gene contains several putative transcriptional regulatory sites including TATA box, cAMP response element, NF-kappaB and AP-1. It showed promoter activity inducible by lipopolysaccharide in vascular smooth muscle cells. Rat B1 receptor mRNA was found to be alternatively spliced and induced by lipopolysaccharide treatment in a wide range of tissues, such as the salivary gland, testis, kidney, lung, heart, prostate and aorta. The deduced rat B1 receptor amino acid sequence is 71% homologous to human and rabbit counterparts, and 89% homologous to the mouse counterpart. The expressed B1 receptor in HEK293 cells displayed a rank order of affinity for the kinin peptides: des-Arg9-BK>Lys-des-Arg9-BK approximately des-Arg9, Leu8-BK>Sar-Tyr-epsilonAhx-Lys-[D-betaNal7, Ile8]-des-Arg9-BK>Sar-Tyr-epsilonAhx-Lys-des-Arg9-BK>>BK>> Hoe140. These results indicate that the cloned gene encodes a functional rat B1 receptor.
Collapse
Affiliation(s)
- A Ni
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA
| | | | | | | |
Collapse
|
34
|
Ni A, Chao L, Chao J. Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation. J Biol Chem 1998; 273:2784-91. [PMID: 9446586 DOI: 10.1074/jbc.273.5.2784] [Citation(s) in RCA: 115] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Expression of the bradykinin B1 receptor gene is up-regulated in vascular smooth muscle cells (VSMCs) in response to a variety of inflammatory stimuli. We isolated the 5'-flanking region of the human bradykinin B1 receptor gene and examined its promoter activity by transient transfection analysis. This region (-2582 to +34) showed promoter activity inducible by lipopolysaccharide (LPS), tumor necrosis factor alpha (TNF-alpha), and interleukin-1beta (IL-1beta) in VSMCs. Further deletion analysis revealed that constructs containing 111 base pairs of 5'-flanking sequence were sufficient for transcriptional induction. Mutagenesis of a nuclear factor kappaB (NF-kappaB)-like site at -64 to -55 abolished most of the LPS, TNF-alpha, and IL-1beta inducibility, whereas a mutation of a cyclic AMP response element at -50 to -43 markedly reduced the basal promoter activity, and a mutation of the activator protein 1 (AP-1) site at -78 to -72 had minimal effects. Nuclear extracts from LPS, TNF-alpha, and IL-1beta-treated VSMCs, IL-1beta-treated human hepatoma HepG2, and human lung fibroblast IMR-90 cells showed strong inducible binding activity to the NF-kappaB-like site by gel shift assays. These results demonstrated that NF-kappaB-like nuclear factor was involved in the inducible expression of the human bradykinin B1 receptor gene during inflammatory processes.
Collapse
MESH Headings
- Amino Acid Sequence
- Base Sequence
- Cloning, Molecular
- DNA Mutational Analysis
- Gene Expression Regulation
- Genes, Reporter
- Humans
- Inflammation
- Interleukin-1/pharmacology
- Lipopolysaccharides/pharmacology
- Molecular Sequence Data
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/metabolism
- Mutagenesis, Site-Directed
- NF-kappa B/metabolism
- Promoter Regions, Genetic
- Protein Binding
- Receptor, Bradykinin B1
- Receptors, Bradykinin/biosynthesis
- Receptors, Bradykinin/genetics
- Tumor Necrosis Factor-alpha/pharmacology
Collapse
Affiliation(s)
- A Ni
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
| | | | | |
Collapse
|
35
|
Abstract
We have previously purified and cloned human kallistatin and rat kallikrein-binding protein (RKBP), which are tissue kallikrein inhibitors belonging to the serine proteinase inhibitor superfamily. In this study, we have cloned and sequenced the gene encoding rat kallistatin with Phe-Phe-Ser-Ala-Gln at positions P2-P3', which is identical to the reactive center of human kallistatin. Rat kallistatin is highly similar to human kallistatin, sharing 68% and 57% sequence identity at the cDNA and the amino acid levels. The rat kallistatin gene exists in a single copy and is located on chromosome 6. An SphI RFLP is found between SHR and WKY rats at or near the rat kallistatin gene locus. Two amino acid polymorphisms of the rat kallistatin gene between these two strains were found by sequence analysis. A candidate promoter in the 5'-flanking region (109 bp) of the rat kallistatin gene has been identified by reporter assays. The expression of rat kallistatin in the liver is growth-dependent and down-regulated during acute phase inflammation. Recombinant rat kallistatin produced in E. coli is able to bind to tissue kallikrein, and the interaction is inhibited by heparin. These characteristics define rat kallistatin as the counterpart of human kallistatin.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Base Sequence
- Carrier Proteins/genetics
- Carrier Proteins/metabolism
- Chromosome Mapping
- Cloning, Molecular
- DNA, Complementary/genetics
- Escherichia coli/genetics
- Gene Dosage
- Gene Expression Regulation, Developmental/physiology
- Genes/genetics
- Kallikreins/metabolism
- Liver/chemistry
- Molecular Sequence Data
- Point Mutation/genetics
- Polymorphism, Restriction Fragment Length
- Promoter Regions, Genetic/genetics
- RNA, Messenger/analysis
- Rats
- Rats, Inbred Strains
- Recombinant Fusion Proteins/metabolism
- Restriction Mapping
- Sequence Analysis, DNA
- Sequence Homology, Amino Acid
- Sequence Homology, Nucleic Acid
- Serpins/genetics
- Serpins/metabolism
Collapse
Affiliation(s)
- K X Chai
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425-2211, USA
| | | | | | | | | | | | | |
Collapse
|
36
|
Chai KX, Ni A, Wang D, Ward DC, Chao J, Chao L. Genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene BDKRB1. Genomics 1996; 31:51-7. [PMID: 8808279 DOI: 10.1006/geno.1996.0008] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We have cloned and sequenced the human B1 bradykinin receptor gene (BDKRB1), which contains an uninterrupted coding exon. A putative promoter was identified by linking various lengths of the 5'-flanking region of the B1 receptor gene coding sequence to a CAT reporter and assaying for CAT activity. Deletion analysis showed that a 300-bp fragment in the promoter region is sufficient to direct the synthesis of the reporter and that an enhancer-like element is present between -1842 and -812. A genomic Southern blot using the B1 cDNA revealed that the receptor is encoded by a single-copy gene. The gene is located on chromosome 14q32.1-q32.2, in close proximity to the B2 receptor gene. Northern blot analysis identified a 1.7- to 1.8-kb mature mRNA transcript of the B1 receptor gene in the kidney and pancreas. A widespread tissue distribution of the B1 gene expression was identified by RT-PCR-Southern blot analysis using specific oligonucleotide probes.
Collapse
MESH Headings
- Chloramphenicol O-Acetyltransferase/genetics
- Chromosome Mapping
- Chromosomes, Human, Pair 14/genetics
- Cloning, Molecular
- DNA, Complementary/genetics
- Enhancer Elements, Genetic
- Exons
- Gene Expression
- Genes, Reporter
- Humans
- In Situ Hybridization, Fluorescence
- Kidney/metabolism
- Pancreas/metabolism
- Polymerase Chain Reaction
- Promoter Regions, Genetic
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptor, Bradykinin B1
- Receptor, Bradykinin B2
- Receptors, Bradykinin/genetics
- Sequence Deletion
- Tissue Distribution
Collapse
Affiliation(s)
- K X Chai
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425, USA
| | | | | | | | | | | |
Collapse
|
37
|
Ni A, Everson S, Li Y, Ward ME. [Species-specific monoclonal antibodies against the major outer membrane protein (MOMP) of Chlamydia trachomatis]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1995; 17:428-33. [PMID: 9208568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The synthesized one quarter N-terminal MOMP of C. trachomatis was used for primary immunization of three male BALB/c mice (8 weeks of age), and the boost with C. trachomatis L1/440/Bu elementary bodies (EBs) was followed on day 14. Spleen cells from one mouse with good response of immunization were fused with murine myeloma NS-1 cells on day 24. The hybrid cell suspension was seeded into the wells of 96-well microtest plates which contained macrophage feeder layers. Anti-chlamydial antibodies in culture fluids were screened by ELISA with 1/4 MOMP & L1 EBs coated 96-well trays. Positive wells were cloned by limiting dilution. Four clones which secreted immunoglobulin G1 & G2a class were obtained after elimination of those clones that produced antibodies to C. psittaci strain EAE, C. pneumoniae strain ATCC VR1310 and uninfected BGMK cells. In micro-IF test, we found that the all four clones of MAbs reacted with our laboratory prepared L1, L2, A, B, C, E EBs, L2 tissue culture inclusions, as well as the EBs of all 15 standard serovars of C. trachomatis. The titers of their ascites were more than 1:12,800 in micro-IF test. It was shown that the four clones of MAbs reacted predominantly with 40,000 MOMP of C. trachomatis L1 in Western blot.
Collapse
Affiliation(s)
- A Ni
- PUMC Hospital, CAMS, Beijing
| | | | | | | |
Collapse
|
38
|
Ni A, Wang H, Dong P. [Chlamydia pneumoniae infection in patients with pneumonia, bronchitis and acute upper respiratory tract infection in Beijing]. Zhonghua Nei Ke Za Zhi 1995; 34:388-91. [PMID: 8582186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
A prospective study for C. pneumoniae infection was conducted in 134 patients with acute respiratory disease and 134 matched patients with other medical reasons from January to May 1994 in Beijing. The positive rate of micro-IF (MIF) IgG antibodies was 93% (125/134) and 89% (119/134) respectively (0.1 < P < 0.25) and the geometric mean titers (GMT) were not found to be significant (55.9 +/- 4.2 vs 41.7 +/- 2.8, 0.1 < P < 0.20). Ten patients, four (4/30) with pneumonia and six (6/81) with bronchitis were serologically diagnosed as having recent C. pneumoniae infection. Chronic bronchitis was statistically more frequent in patients with C. pneumoniae infection than those without (0.025 < P < 0.05). Patients with chronic bronchitis (GMT, 87.1 +/- 3.9; n = 36) tended to have higher IgG titers than those without (GMT, 47.6 +/- 4.1; n = 98, 0.02 < P < 0.05). Culture of retro-pharyngeal swab specimens for C. pneumoniae was negative in the all 134 studied patients.
Collapse
Affiliation(s)
- A Ni
- Department of Clinical Laboratories, Peking Union Medical College Hospital, Beijing
| | | | | |
Collapse
|
39
|
Abstract
The 26-residue peptide melittin present in bee venom has been shown to bind calmodulin tightly. In this study we synthesized the following series of deletion peptides of melittin by the solid-phase method: Mel12, Mel13, Mel14, Mel15, Mel15F. The results of this study show that the deletion peptides Mel14 and Mel15 have almost the same binding activity as the intact native peptide. Each deletion peptide forms a 1:1 complex with calmodulin according to electrophoresis analysis. When the tryptophanyl residue of Mel15 was replaced by the phenylalaninyl residue, the dissociation constant of the peptide-calmodulin complex increased. This shows the importance of the tryptophanyl residue for binding to calmodulin.
Collapse
Affiliation(s)
- L Liu
- Institute of Polymer Chemistry, Nankai University, Tianjin, China
| | | | | | | | | |
Collapse
|